Enlivex Therapeutics (NASDAQ:ENLV) Receives Buy Rating from D. Boral Capital

Enlivex Therapeutics (NASDAQ:ENLV – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at D. Boral Capital in a report released on Monday,Benzinga reports. They presently have a $13.00 target price on the stock. Enlivex Therapeutics Stock Down 16.0% Shares of NASDAQ:ENLV opened at $1.05 on Monday. The business has a 50 […]

Leave a Reply

Your email address will not be published.

Previous post DA Davidson Reiterates “Buy” Rating for Crane NXT (NYSE:CXT)
Next post How to Make the Most of the 2025 Silverstone Festival: 10 Unmissable Highlights